It has been shown that tumor subtype also plays a role in terms of median time interval from primary diagnosis to the development of brain metastases, and studies have demonstrated shorter intervals for triple negative and HER2-positive tumors, and longer intervals for estrogen receptor-positive tumors [17]. This evidence concerns the gene ERBB2 and neoplasm.